Journal of Internal Medicine Concepts & Practice ›› 2022, Vol. 17 ›› Issue (06): 441-446.doi: 10.16138/j.1673-6087.2022.06.004
• Original article • Previous Articles Next Articles
CHEN Yinga, ZHANG Chenlia, YAO Weiyanb()
Received:
2022-06-03
Online:
2022-12-30
Published:
2023-02-27
CLC Number:
CHEN Ying, ZHANG Chenli, YAO Weiyan. Efficacy and safety of selective granulocyte and monocyte adsorptive apheresis in treatment of moderate to severe inflammatory bowel disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 441-446.
项目 | 治疗前 | 治疗后 | 治疗前-治疗后 | t/Z | P |
---|---|---|---|---|---|
UC(分) | 9.4 | 0.000 | |||
梅奥评分 | 8.2±2.6 | 3.0±2.2 | 5.2±2.8 | ||
UCEIS评分 | 5.9±2.5 | 2.5±1.9 | 3.4±2.1 | 8.0 | 0.000 |
MES评分 | 3.0(3.0,3.0) | 1.0(1.0,2.0) | 1.0(1.0,2.0) | -4.3 | 0.000 |
Baron评分 | 2.0(1.3,3.0) | 1.0(1.0,1.0) | 1.0(0.0,1.5) | -3.5 | 0.000 |
CD(分) | 7.1 | 0.000 | |||
CDAI评分 | 309.4±94.5 | 179.8±99.7 | 129.6±58.0 | ||
CDEIS评分 | 16.8±9.3 | 5.8±4.8 | 11.0±8.0 | 3.6 | 0.011 |
WBC(×109) | 6.6(5.3,8.7) | 6.5(5.5,7.7) | 0.5(-0.8,1.5) | -1.2 | 0.246 |
N% | 68.2±10.5 | 66.7±10.5 | 2.2±11.7 | 0.8 | 0.445 |
L% | 22.6±8.6 | 25.0±9.5 | -2.6±9.5 | -1.5 | 0.138 |
M% | 7.0±25.3 | 6.4±2.4 | 0.2±2.4 | 1.6 | 0.117 |
Hb(g/L) | 108.5±25.3 | 114.2±24.4 | -5.0±13.0 | -2.7 | 0.010 |
PLT(×109) | 289.1±113.4 | 267.1±99.5 | 9.9±65.8 | 1.9 | 0.067 |
Alb(g/L) | 32.9±5.8 | 36.6±6.8 | -3.8±4.9 | -4.6 | 0.000 |
CRP(mg/L) | 10.5(3.2,29.1) | 3.2(1.0,9.3) | 3.8(-0.5,12.0) | -2.7 | 0.007 |
ESR(mm/1h) | 17.0(8.0,29.8) | 14.0(10.0,26.5) | 1.0(-6.5,10.0) | -7.1 | 0.480 |
每日大便次数(次) | 4.0(3.0,8.0) | 2.0(1.0,3.3) | 2.0(0.0,3.3) | -4.2 | 0.000 |
项目 | 无效组(n=5) | 有效组(n=23) | t/Z | P |
---|---|---|---|---|
年龄(岁) | 50.6±16.4 | 41.1±13.9 | 1.3 | 0.189 |
性别 | 0.053 | |||
男性 | 5(31.3) | 11(68.8) | ||
女性 | 0(0.0) | 12(100.0) | ||
病程(月) | 12.0(7.5,68.0) | 27.0(7.0,79.0) | -0.7 | 0.471 |
每日大便次数(次) | 7.0(3.0,9.5) | 54(3.0,8.0) | 0.718 | |
BMI(kg/m2) | 19.37(16.8,23.0) | 21.0(20.0,23.9) | -0.9 | 0.352 |
蒙特利尔分型 | 0.689 | |||
E1 | 0(0.0) | 1(100.0) | ||
E2 | 1(10.0) | 9(90.0) | ||
E3 | 4(23.5) | 13(76.5) | ||
既往药物史 | 0.254 | |||
初发 | 0(0.0) | 3(100.0) | ||
ASA无效 | 0(0.0) | 6(100.0) | ||
激素依赖 | 2(16.7) | 10(83.3) | ||
激素抵抗 | 2(40.0) | 3(60.0) | ||
生物制剂失应答 | 1(50.0) | 1(50.0) | ||
机会性感染 | 0.015 | |||
无 | 1(5.0) | 19(95.0) | ||
有 | 4(50.0) | 4(50.0) | ||
梅奥评分(分) | 10.2±2.5 | 8.2±2.6 | 1.6 | 0.118 |
Truelove & Witts | 0.333 | |||
中度 | 1(7.7) | 12(92.3) | ||
重度 | 4(26.7) | 11(73.3) | ||
UCEIS评分(分) | 7.0±2.5 | 5.8±2.4 | 1.0 | 0.314 |
WBC(×109/L) | 6.66(4.3,9.0) | 7.02(6.0,9.1) | -0.8 | 0.418 |
Hb(g/L) | 84.6±20.2 | 115.4±26.6 | -2.4 | 0.022 |
PLT(×109/L) | 224.6±96.4 | 276.1±113.6 | -0.9 | 0.356 |
Alb(g/L) | 29.8±3.1 | 34.8±5.0 | -2.1 | 0.042 |
ESR(mm/1h) | 17.0(8.5,67.5) | 16.0(6.0,24.0) | -0.9 | 0.368 |
CRP(mg/L) | 14.0(8.7,30.1) | 6.0(3.0,22.0) | -1.3 | 0.197 |
项目 | 无效组(n=3) | 有效组(n=7) | t/Z | P |
---|---|---|---|---|
年龄(岁) | 20.7±7.2 | 28.9±10.3 | -1.2 | 0.253 |
性别 | 1.000 | |||
男性 | 1(25.0) | 3(75.0) | ||
女性 | 2(33.3) | 4(66.7) | ||
病程(月) | 27.3±39.7 | 83.1±59.8 | -1.5 | 0.183 |
每日大便次数(次) | 2.7±0.6 | 4.0±2.7 | -0.8 | 0.437 |
BMI(kg/m2) | 18.8±0.8 | 19.2±2.0 | -0.3 | 0.760 |
蒙特利尔分型 | ||||
确诊年龄(A) | 0.533 | |||
A1 | 1(100) | 0(0.0) | ||
A2 | 2(25) | 6(75.0) | ||
A3 | 0(0) | 1(100) | ||
病变部位(L) | 1.000 | |||
L1+L4 | 0(0) | 1(100) | ||
L3 | 3(33) | 6(67) | ||
疾病行为(B) | 1.000 | |||
B2 | 1(50) | 1(50) | ||
B3 | 2(25) | 6(75) | ||
肛周疾病(p) | 1.000 | |||
无 | 1(20) | 4(80) | ||
有 | 2(40) | 3(60) | ||
既往药物史 | 0.800 | |||
初发 | 1(33) | 2(67) | ||
ASA无效 | 0(0) | 1(100) | ||
激素依赖 | 0(0) | 2(100) | ||
生物制剂失应答 | 2(50) | 2(50) | ||
机会性感染 | 1.000 | |||
无 | 1(25) | 3(75) | ||
有 | 2(33) | 4(67) | ||
CDAI评分(分) | 243.1±25.8 | 337.7±100.2 | -1.6 | 0.157 |
手术史 | 1.000 | |||
无 | 1(25) | 3(75) | ||
有 | 2(33) | 4(67) | ||
CDEIS评分(分) | 22.6±8.1 | 15.0±8.5 | 1.1 | 0.301 |
WBC(×109/L) | 8.2±6.0 | 6.1±2.0 | 0.6 | 0.614 |
Hb(g/L) | 97.0±19.5 | 108.0±14.9 | -1.0 | 0.354 |
PLT(×109/L) | 453.0±50.8 | 307.4±83.6 | 2.8 | 0.025 |
Alb(g/L) | 29.3±4.5 | 30.6±8.2 | -0.2 | 0.815 |
ESR(mm/1h) | 52.7±32.6 | 19.0±10.3 | 1.8 | 0.212 |
CRP(mg/L) | 46.2±46.6 | 21.3±28.7 | 1.1 | 0.321 |
[1] |
Windsor JW, Kaplan GG. Evolving epidemiology of IBD[J]. Curr Gastroenterol Rep, 2019, 21(8): 40.
doi: 10.1007/s11894-019-0705-6 pmid: 31338613 |
[2] | Schreiner P, Neurath MF, Ng SC, et al. Mechanism-based treatment strategies for IBD[J]. Inflamm Intest Dis, 2019, 4, 79-96. |
[3] |
Lai YM, Yao WY, He Y, et al. Adsorptive granulocyte and monocyte apheresis in the treatment of ulcerative colitis[J]. Gut Liver, 2017, 11(2): 216-225.
doi: 10.5009/gnl15408 pmid: 27843131 |
[4] | 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中华炎性肠病杂志, 2018, 2(3): 173-190. |
[5] |
Pabla BS, Schwartz DA. Assessing severity of disease in patients with ulcerative colitis[J]. Gastroenterol Clin North Am, 2020, 49(4): 671-688.
doi: 10.1016/j.gtc.2020.08.003 URL |
[6] |
Gajendran M, Loganathan P, Catinella AP, et al. A comprehensive review and update on Crohn’s disease[J]. Dis Mon, 2018, 64(2): 20-57.
doi: S0011-5029(17)30153-0 pmid: 28826742 |
[7] | M’Koma AE. Inflammatory bowel disease[J]. Medicina (Kaunas), 2022, 58(5): 567. |
[8] | Yamamoto T, Shimoyama T, Umegae S, et al. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing[J]. Clin Transl Gastroenterol, 2018, 9(3): 136. |
[9] | Mohammed Vashist N, Samaan M, Mosli MH, et al. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis[J]. Cochrane Database Syst Rev, 2018, 1(1): CD011450. |
[10] |
Kanekura T. Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders[J]. J Dermatol, 2018, 45(8): 943-950.
doi: 10.1111/1346-8138.14471 URL |
[11] |
Litao MK, Kamat D. Erythrocyte sedimentation rate and C-reactive protein: how best to use them in clinical practice[J]. Pediatr Ann, 2014, 43(10): 417-420.
doi: 10.3928/00904481-20140924-10 pmid: 25290132 |
[12] |
Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis[J]. J Clin Apher, 2001, 16(1): 1-9.
doi: 10.1002/jca.1000 pmid: 11309823 |
[13] |
Dignass A, Akbar A, Baumgart DC, et al. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis[J]. Scand J Gastroenterol, 2018, 53(4): 442-448.
doi: 10.1080/00365521.2018.1447598 URL |
[14] |
Saniabadi AR, Tanaka T, Yamamoto T, et al. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease[J]. J Clin Apher, 2019, 34(1): 51-60.
doi: 10.1002/jca.21670 pmid: 30407662 |
[15] |
Sands BE, Katz S, Wolf DC, et al. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn’s disease[J]. Gut, 2013, 62(9): 1288-1294.
doi: 10.1136/gutjnl-2011-300995 URL |
[16] |
Kuwaki K, Mitsuyama K, Kaida H, et al. A longitudinal study of FDG-PET in Crohn disease patients receiving granulocyte/monocyte apheresis therapy[J]. Cytotherapy, 2016, 18(2): 291-299.
doi: 10.1016/j.jcyt.2015.10.010 pmid: 26700210 |
[17] |
Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients[J]. Dig Liver Dis, 2008, 40(9): 731-736.
doi: 10.1016/j.dld.2008.02.012 URL |
[1] | LIU Ping, XIAO Yuan, WANG Xinqiong, LU Tingwei, ZHAO Xuesong, YANG Yuanyan. Crohn′s disease in a child with Wiskott-Aldrich syndrome: a case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 349-354. |
[2] | YU Youyou, ZENG Junxiang, LUO Ting, DENG Lin, PAN Xiujun. Comparison of results and evaluation of performance of three different ELISA kits for detection of ASCA [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(04): 454-459. |
[3] | WANG Tingting, ZHENG Naisheng, YUAN Xiangliang, SHEN Lisong. Analysis of structural characteristics of gut microbiome in colitis mice based on 16S rRNA high-throughput sequencing [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(03): 263-270. |
[4] | MAO Yulei, ZHOU Tao, TANG Lingyun, ZHANG Hongxin, WANG Zhugang. Influence of Tacr2 on ulcerative colitis in mice [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 578-581. |
[5] | . [J]. Journal of Internal Medicine Concepts & Practice, 2016, 11(05): 296-300. |
[6] | . [J]. Journal of Internal Medicine Concepts & Practice, 2016, 11(02): 84-87. |
[7] | . [J]. Journal of Internal Medicine Concepts & Practice, 2015, 10(05): 381-383. |
[8] | . [J]. Journal of Diagnostics Concepts & Practice, 2015, 14(03): 223-228. |
[9] | . [J]. Journal of Diagnostics Concepts & Practice, 2015, 14(02): 131-135. |
[10] | . [J]. Journal of Diagnostics Concepts & Practice, 2014, 13(06): 579-583. |
[11] | . [J]. Journal of Diagnostics Concepts & Practice, 2008, 7(06): 605-608. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||